Analysis of the Association of Administration of various glucocorticoids with development of acute pancreatitis using US Food and Drug Administration adverse event reporting system (FAERS)

Table 2 The numbers of cases of patients who developed acute pancreatitis (SMQ;20000022) during treatment with glucocorticoids and RORs for the respective glucocorticoids

	Total	Case	RR (%)	ROR (95%CI)	P-value
ALL (PS + SS + C + I)
Cortisol	16,431	146	0.89	1.68 (1.43–1.98)	< 0.001
Cortisone	3580	22	0.61	1.16 (0.76–1.75)	0.49
Prednisolone	50,242	353	0.70	1.33 (1.19–1.47)	< 0.001
Methylprednisolone	23,496	220	0.94	1.77 (1.55–2.02)	< 0.001
Triamcinolone	11,363	50	0.44	0.83 (0.63–1.09)	0.20
Dexamethasone	84,411	387	0.46	0.86 (0.78–0.95)	< 0.01
Betamethasone	3825	24	0.63	1.18 (0.79–1.76)	0.38
PS + SS
Cortisol	2865	16	0.56	1.05 (0.65–1.71)	0.80
Cortisone	640	2	0.31	0.59 (0.16–2.14)	0.78
Prednisolone	19,134	133	0.70	1.31 (1.10–1.55)	< 0.01
Methylprednisolone	9564	82	0.86	1.62 (1.30–2.01)	< 0.001
Triamcinolone	4749	4	0.08	0.16 (0.06–0.41)	< 0.001
Dexamethasone	28,140	190	0.68	1.27 (1.10–1.47)	< 0.01
Betamethasone	1121	11	0.98	1.85 (1.03–3.33)	0.058

Case; the number of reported cases with patients who developed acute pancreatitis during treatment with each glucocorticoid (target drug), Total; number of reported cases for the corresponding glucocorticosteroids, RR reporting ratio (case/total×100), ROR reporting odds ratio, CI confidence interval, PS primarily suspected drug, SS secondarily suspected drug, C concomitant drug, I interacting drug

ISSN: 2055-0294